Drug Product Development for the Back of the Eye
148,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
74 °P sammeln
  • Gebundenes Buch

This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs.
Specific topics covered in this book include: Solution, suspension, gel, nanoparticle, microparticle, and implant dosage formsRefillable and microneedle devicesIntravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of deliveryPhysical methods including iontophoresis for drug deliveryRational selection of routes of administration and delivery systemsNoninvasive and…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
This comprehensive volume discusses approaches for a systematic selection of delivery systems for various classes of therapeutic agents including small molecule, protein, and nucleic acid drugs.

Specific topics covered in this book include:
Solution, suspension, gel, nanoparticle, microparticle, and implant dosage formsRefillable and microneedle devicesIntravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of deliveryPhysical methods including iontophoresis for drug deliveryRational selection of routes of administration and delivery systemsNoninvasive and continuous drug monitoring Regulatory path to drug product developmentClinical endpoints for drug product developmentEmerging and existing drugs and drug targets

Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serves as indispensable resourcefor ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of the eye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering.
Refillable and microneedle devicesIntravitreal, suprachoroidal, intrascleral, transscleral, systemic, and topical routes of deliveryPhysical methods including iontophoresis for drug deliveryRational selection of routesof administration and delivery systemsNoninvasive and continuous drug monitoring Regulatory path to drug product developmentClinical endpoints for drug product developmentEmerging and existing drugs and drug targets

Drug Product Development for the Back of the Eye is authored by renowned ocular drug delivery experts, representing academic, clinical, and industrial organizations and serndustrial organizations and serves as indispensable resource for ophthalmic researchers, drug formulation scientists, drug delivery and drug disposition scientists, as well as clinicians involved in designing and developing novel therapeutics for the back of theeye diseases. This book is also relevant for students in various disciplines including ophthalmology, pharmaceutical sciences, drug delivery, and biomedical engineering.
Autorenporträt
Uday B. Kompella, Ph.D. has been an independent faculty member in the field of drug delivery for 17 years, with ocular drug delivery being a key research focus. Prior to joining University of Colorado in 2008, he served as a faculty member at University of Nebraska for 10 years and at Auburn University for 4 years. Dr. Kompella's research, published in over 100 peer-reviewed articles, is focused on developing new drug and gene delivery approaches for treating neovascular diseases including diabetic retinopathy, age-related macular degeneration, and cancer. Dr. Kompella developed and assessed several drug delivery systems including functionalized nanoparticles, nanoporous microparticles, microparticles, injectable implants, dendrimers, liposomes, and in situ forming gels for ophthalmic applications. Dr. Kompella is a Fellow of the American Association of Pharmaceutical Scientists (2005) and the Association for Research in Vision and Ophthalmology (2010). He was recognized as a Distinguished Scientist in 2006 and as a Distinguished Teacher in 2003 at University of Nebraska Medical Center. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the CastroviejoMedal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas of ophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications. Henry F. Edelhauser, Ph.D. is a world leader in ophthalmic drug delivery, with an academic career spanning over 4 decades in ophthalmic research. After serving as a faculty member at the Medical College of Wisconsin (1966-1989) as an assistant, associate and then full professor, Dr. Edelhauser joined Emory University in 1989 as the Ferst Professor of Ophthalmology and Director of Ophthalmic Research. Dr. Edelhauser published over 230 peer-reviewed articles in the areas ofophthalmic drug delivery, surgical pharmacology, corneal physiology, and ocular toxicology. Dr. Edelhauser made pioneering contributions towards transcorneal, transscleral, and suprachoroidal drug delivery to the eye. During 1990-91, Dr. Edelhauser served as the president of the Association for Research in Vision and Ophthalmology (ARVO).  In 1999 he was awarded the Castroviejo Medal and the Alcon Research Award. In 2000, he received the senior achievement award from the American Academy of Ophthalmology. In 2005, Dr. Edelhauser was recognized with the Procter medal, ARVO's highest honor for his outstanding ophthalmic translational research from basic science to clinical applications.